Pharming Group (NASDAQ:PHAR) Now Covered by Jefferies Financial Group

Research analysts at Jefferies Financial Group assumed coverage on shares of Pharming Group (NASDAQ:PHAR) in a research note issued to investors on Monday, Marketbeat.com reports. The brokerage set a “buy” rating and a $14.00 price target on the stock. Jefferies Financial Group’s target price suggests a potential upside of 60.18% from the company’s previous close.

A number of other equities research analysts also recently commented on PHAR. HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price on shares of Pharming Group in a report on Thursday, October 24th. Oppenheimer dropped their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, October 28th.

Pharming Group Price Performance

Shares of PHAR opened at $8.74 on Monday. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The company’s fifty day moving average price is $8.21 and its 200-day moving average price is $8.13. Pharming Group has a 1-year low of $6.65 and a 1-year high of $13.20. The firm has a market capitalization of $592.88 million, a PE ratio of -33.62 and a beta of 0.05.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group (NASDAQ:PHAR) by 75.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.